在TACE术中应用奥沙利铂联合表柔比星治疗肝癌患者疗效观察

doi:10.3969/j.issn.1672-5069.2015.01.025

Abstract

Xiong Shujun. Application of oxaliplatin and epirubicin through transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 86-88.

References

[1] 刘家贺,于全成. 奥沙利铂联合表柔比星经导管肝动脉化疗栓塞介入治疗原发性肝癌临床分析. 现代医药卫生,2014,30（5）:743-744.
[2] 刘亚贤,赵宏然,赵海. 奥沙利铂联合表柔比星在原发肝癌介入治疗的疗效观察. 齐齐哈尔医学院学报,2012,33（1）:35-36.
[3] 李海涛,解皓. 奥沙利铂联合表柔比星、氟尿嘧啶在中晚期原发性肝癌介入治疗中的疗效观察. 临床合理用药杂志,2012,5（28）:8-9.
[4] 李绮云,陈永锋,林王美,等. 表柔比星联合奥沙利铂及替吉奥治疗晚期胃癌的近期疗效分析. 肿瘤基础与临床,2012,25（4）:294-296.
[5] 谢勋鹏,陈萍,张莉莉,等. 奥沙利铂联合吡柔比星和氟尿嘧啶治疗晚期肝癌的临床疗效分析. 现代肿瘤医学,2012,20（10）:2138-2140.
[6] 姜西玲,赵新汉. 奥沙利铂联合5-FU和吡柔比星治疗晚期胃癌临床疗效分析. 现代肿瘤医学,2010,18（1）:117-118.
[7] 肖作珍,肖瑞,姜继臣. 奥沙利铂联合表柔比星和5-FU治疗多发转移性胃癌的临床观察.中华肿瘤防治杂志,2010,17（12）:946-947.
[8] 王宁,张阳德,廖明媚,等. 盐酸表柔比星联合奥沙利铂对肝癌HepG2细胞凋亡的抑制作用. 中国临床药理学与治疗学,2013,18（5）:490-494.
[9] 廖明初,艾小红. 奥沙利铂联合恩度介入治疗原发性肝癌疗效观察. 中南医学科学杂志,2013,41（5）:500-504.
[10] 卓恩挺,陈雪莲,王连臣,等. 奥沙利铂联合卡培他滨治疗老年胃肠恶性肿瘤的临床疗效分析. 实用癌症杂志,2013,28（6）:686-688.
[11] 雷林瑜,梅家转.奥沙利铂联合替吉奥胶囊治疗晚期胃癌的观察. 医药论坛杂志,2014,35（2）:60-61.
[12] 王琼,王南瑶,曾洁,等. 多柔比星脂质体对比表柔比星联合奥沙利铂、亚叶酸钙和氟尿嘧啶治疗晚期胃癌的临床观察.临床肿瘤学杂志,2011,16（6）:542-545.
[13] 钟锡明,范钰,邱志运. 奥沙利铂为主的化疗方案治疗晚期胃癌的临床观察. 现代肿瘤医学,2010,18（6）:1177-1179.
[14] 欧洲呼吸学会和欧洲胸外科医师学会恶性胸膜间皮瘤诊疗指南. 中国肺癌杂志,2010,12（10）:999-1021.
[15] 杨朝旭,秦叔逵. 奥沙利铂治疗原发性肝癌的临床研究进展. 临床肿瘤学杂志,2010,15（9）:845-855.
[16] 颜鹏,方志勇,向华. 奥沙利铂及重组人血管内皮抑素经肝动脉灌注联合TACE治疗原发性肝癌.介入放射学杂志,2013,22（2）:121-124.
[17] 杨葛亮,翟笑枫. 原发性肝癌系统性化疗的临床进. 肿瘤,2014,34（1）:91-96.
[18] 赵全德,董灵,李向东. 吉西他滨联合表柔比星治疗转移性肝癌的临床研究. 现代肿瘤医学,2011,19（1）:116-117.
[19] 华燕艳,李杰,杨章庚,等. 含奥沙利铂方案TACE治疗原发性肝癌的临床观察. 临床肿瘤学杂志,2011,16（5）:456-459.
[20] 王少雷,李森,魏宏,等. 奥沙利铂与吡喃阿霉素介入治疗原发性肝癌的比较研究. 介入放射学杂志,2012,21（9）:738-742.

Application of oxaliplatin and epirubicin through transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Chen Xiang, Wang Baolin, Wu Chen, et al.. Efficacy of transcatheter arterial chemoembolization and radion implantation in the treatment of patients with primary liver cancer and its impact on hepatic expressions of TRF1 and TRF2 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 121-124.